Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus (BeCarma)
Latest Information Update: 19 Feb 2024
Price :
$35 *
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms BeCarma
- 15 Feb 2024 Status changed from recruiting to discontinued.
- 29 Sep 2023 Planned End Date changed from 28 Feb 2024 to 28 Feb 2025.
- 08 Nov 2021 New trial record